Standard Treatment Regimens for Nongonococcal Urethritis Have Similar but Declining Cure Rates: A Randomized Controlled Trial

被引:155
作者
Manhart, Lisa E. [1 ,2 ]
Gillespie, Catherine W. [1 ,6 ]
Lowens, M. Sylvan [5 ]
Khosropour, Christine M. [1 ]
Colombara, Danny V. [1 ]
Golden, Matthew R. [3 ,5 ]
Hakhu, Navneet R. [4 ]
Thomas, Katherine K. [3 ]
Hughes, James P. [4 ]
Jensen, Nicole L. [3 ]
Totten, Patricia A. [3 ]
机构
[1] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA
[3] Univ Washington, Dept Med, Seattle, WA 98104 USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98104 USA
[5] STD Program, Seattle, WA USA
[6] Childrens Natl Med Ctr, Washington, DC 20010 USA
基金
美国国家卫生研究院;
关键词
urethritis; treatment; Mycoplasma genitalium; Chlamydia trachomatis; randomized trial; MYCOPLASMA-GENITALIUM; DOUBLE-BLIND; AZITHROMYCIN; MEN; INFECTION; THERAPY; AMPLIFICATION; MOXIFLOXACIN; ERADICATION; PERSISTENCE;
D O I
10.1093/cid/cis1022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Azithromycin or doxycycline is recommended for nongonococcal urethritis (NGU); recent evidence suggests their efficacy has declined. We compared azithromycin and doxycycline in men with NGU, hypothesizing that azithromycin was more effective than doxycycline. Methods. From January 2007 to July 2011, English-speaking males >= 16 years, attending a sexually transmitted diseases clinic in Seattle, Washington, with NGU (visible urethral discharge or >= 5 polymorphonuclear leukocytes per high-power field [PMNs/HPF]) were eligible for this double-blind, parallel-group superiority trial. Participants received active azithromycin (1 g) + placebo doxycycline or active doxycycline (100 mg twice daily for 7 days) + placebo azithromycin. Urine was tested for Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), Urea plasma urealyticum biovar 2 (UU-2), and Trichomonas vaginalis (TV) using nucleic acid amplification tests. Clinical cure (<5 PMNs/HPF with or without urethral symptoms and absence of discharge) and microbiologic cure (negative tests for CT, MG, and/or UU-2) were determined after 3 weeks. Results. Of 606 men, 304 were randomized to azithromycin and 302 to doxycycline; CT, MG, TV, and UU-2 were detected in 24%, 13%, 2%, and 23%, respectively. In modified intent-to-treat analyses, 172 of 216 (80%; 95% confidence interval [CI], 74%-85%) receiving azithromycin and 157 of 206 (76%; 95% CI, 70%-82%) receiving doxycycline experienced clinical cure (P = .40). In pathogen-specific analyses, clinical cure did not differ by arm, nor did microbiologic cure differ for CT (86% vs 90%, P = .56), MG (40% vs 30%, P = .41), or UU-2 (75% vs 70%, P = .50). No unexpected adverse events occurred. Conclusions. Clinical and microbiologic cure rates for NGU were somewhat low and there was no significant difference between azithromycin and doxycycline. Mycoplasma genitalium treatment failure was extremely common. Clinical Trials Registration. NCT00358462.
引用
收藏
页码:934 / 942
页数:9
相关论文
共 50 条
  • [31] A Randomized Controlled Trial Comparing the Treatment of Patients Tested for Chlamydia and Gonorrhea After a Rapid Polymerase Chain Reaction Test Versus Standard of Care Testing
    May, Larissa
    Ware, Chelsea E.
    Jordan, Jeanne A.
    Zocchi, Mark
    Zatorski, Catherine
    Ajabnoor, Yasser
    Pines, Jesse M.
    SEXUALLY TRANSMITTED DISEASES, 2016, 43 (05) : 290 - 295
  • [32] Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: A multicenter cluster randomized controlled trial (ENGAGE)
    Livingston, Patricia M.
    Craike, Melinda J.
    Salmon, Jo
    Courneya, Kerry S.
    Gaskin, Cadeyrn J.
    Fraser, Steve F.
    Mohebbi, Mohammadreza
    Broadbent, Suzanne
    Botti, Mari
    Kent, Bridie
    CANCER, 2015, 121 (15) : 2646 - 2654
  • [33] Which trial do we need? A randomized controlled trial comparing oral antibiotic monotherapy versus standard of care as antibiotic continuation treatment for the treatment of left-sided native valve bacterial endocarditis
    Van Laethem, Johan
    CLINICAL MICROBIOLOGY AND INFECTION, 2025, 31 (03) : 319 - 322
  • [34] An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
    Sarojvisut, Phahol
    Apisarnthanarak, Anucha
    Jantarathaneewat, Kittiya
    Sathitakorn, Ornnicha
    Pienthong, Thanus
    Mingmalairak, Chatchai
    Warren, David K.
    Weber, David J.
    INFECTION AND CHEMOTHERAPY, 2023, 55 (01) : 50 - 58
  • [35] Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R2 randomized controlled trial
    Gafar, Fajri
    Yunivita, Vycke
    Fregonese, Federica
    Apriani, Lika
    Aarnoutse, Rob E.
    Ruslami, Rovina
    Menzies, Dick
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 64 (01)
  • [36] Topical petrolatum gel alone versus topical silver sulfadiazine with standard gauze dressings for the treatment of superficial partial thickness burns in adults: A randomized controlled trial
    Genuino, Glenn Angelo S.
    Baluyut-Angeles, Kathrina Victoria
    Espiritu, Andre Paolo T.
    Lapitan, Marie Carmelo. M.
    Buckley, Brian S.
    BURNS, 2014, 40 (07) : 1267 - 1273
  • [37] Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial
    Van Vlierberghe, H
    Leroux-Roels, G
    Adler, M
    Bourgeois, N
    Nevens, F
    Horsmans, Y
    Brouwer, J
    Colle, I
    Delwaide, J
    Brenard, R
    Bastens, B
    Henrion, J
    de Vries, RA
    de Galocsy, C
    Michielsen, P
    Robaeys, G
    Bruckers, L
    JOURNAL OF VIRAL HEPATITIS, 2003, 10 (06) : 460 - 466
  • [38] An initial randomized controlled trial of behavioral activation for treatment of concurrent crystal methamphetamine dependence and sexual risk for HIV acquisition among men who have sex with men
    Mimiaga, Matthew J.
    Pantalone, David W.
    Biello, Katie B.
    Hughto, Jackie M. White
    Frank, John
    O'Cleirigh, Conall
    Reisner, Sari L.
    Restar, Arjee
    Mayer, Kenneth H.
    Safren, Steven A.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2019, 31 (09): : 1083 - 1095
  • [39] Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial
    Manzini, Paola Maria
    Ciccone, Giovannino
    De Rosa, Francesco Giuseppe
    Cavallo, Rossana
    Ghisetti, Valeria
    D'Antico, Sergio
    Galassi, Claudia
    Saccona, Fabio
    Castiglione, Anna
    Birocco, Nadia
    Francisci, Tiziana
    Hu, Huijing
    Pecoraro, Clara
    Danielle, Franca
    Labanca, Luciana
    Bordiga, Anna Maria
    Lorenzi, Marco
    Camisasca, Giovanni
    Giachino, Osvaldo
    Pagliarino, Mauro
    Ottone, Piero
    Scuvera, Ilvana Tiziana Donatella
    Guaschino, Roberto
    Freilone, Roberto
    Berti, Pierluigi
    Pittaluga, Fabrizia
    Avolio, Maria
    Costa, Cristina
    Raso, Samuele
    Nucci, Aurora
    Milan, Massimo
    Bafa, Alessandra
    Russo, Alessandra
    Tornello, Antonella
    Maddalena, Laura
    Delios, Grazia
    Marletto, Fabio Paolo
    De Micheli, Anna Grazia
    Mattei, Alessio
    Baldassano, Stefano
    Canta, Francesca
    Russo, Maria Luisa
    Bergamo, Daniele
    Vitale, Francesco
    Liccardi, Marco Maria
    Chinaglia, Alessandra
    Calcagno, Andrea
    Converso, Marcella
    Aldieri, Chiara
    Libanore, Valentina
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [40] Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID-19: A randomized double-blind placebo-controlled trial
    Guzman-Esquivel, Jose
    Galvan-Salazar, Hector R.
    Guzman-Solorzano, Hannah P.
    Cuevas-Velazquez, Andrea C.
    Guzman-Solorzano, Jose A.
    Mokay-Ramirez, Karen A.
    Paz-Michel, Brenda A.
    Murillo-Zamora, Efren
    Delgado-Enciso, Josuel
    Melnikov, Valery
    Delgado-Enciso, Osiris G.
    Rodriguez-Sanchez, Iram P.
    Martinez-Fierro, Margarita L.
    Rojas-Larios, Fabian
    Walle-Guillen, Mireya
    Cardenas-Aguilar, Citlaly B.
    Beas-Guzman, Oscar
    Chaviano-Conesa, Daniel
    Garcia-Garcia, Hossana S.
    Delgado-Enciso, Ivan
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2022, 49 (03)